CN102772398A - Application of dihydromyricetin in preparation of drug preventing and treating influenza - Google Patents
Application of dihydromyricetin in preparation of drug preventing and treating influenza Download PDFInfo
- Publication number
- CN102772398A CN102772398A CN2011101234718A CN201110123471A CN102772398A CN 102772398 A CN102772398 A CN 102772398A CN 2011101234718 A CN2011101234718 A CN 2011101234718A CN 201110123471 A CN201110123471 A CN 201110123471A CN 102772398 A CN102772398 A CN 102772398A
- Authority
- CN
- China
- Prior art keywords
- dihydromyricetin
- preparation
- influenza
- application
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Belonging to the technical field of drug processing, the invention relates to application of dihydromyricetin in preparation of a drug preventing and treating influenza, and solves the problem of preventing and treating influenza with dihydromyricetin. Application of dihydromyricetin in preparation of the drug preventing and treating influenza has the advantages of good anti-influenza virus effect, remarkable curative effect, and no toxic or side effect. The preparation method of the influenza drug consists of: mixing dihydromyricetin with starch uniformly, adding a starch slurry and conducting stirring to prepare a soft material, carrying out granulation, and performing drying, then adding aerosol, implementing grain finishing and tabletting so as to obtain 1000 tablets, each of which weighs about 0.5g.
Description
Technical field
The present invention relates to dihydromyricetin and prevent and treat the application in the influenza medicine, belong to the medicine processing technique field in preparation.
Background technology
Influenza is a kind of acute respiratory infectious disease, and very strong infectiousness is arranged.Existing epidemiologic data demonstration whenever once is very popular at a distance from about 10 years.Influenza breaks out, distributes, popularly then take place frequently in all parts of the world, and serious threat old people and other high-risk group's health and lives is like the chronic heart, pneumonopathy or diabetes.Traditional treatment of influenza method is suitably to have a rest and symptomatic treatment, is the inevitable development of treatment means but treat to cause of disease, is an important topic of study of pharmacy to the research that prevents and treats the influenza medicine always; Therefore, the present invention provides the application of dihydromyricetin in preventing and treating the influenza medicine, and this influenza medicine has the effect of good resisiting influenza virus, and is evident in efficacy, and has no side effect.
The structural formula of dihydromyricetin:
Summary of the invention
To the problem that prior art exists, the present invention is intended to open dihydromyricetin and prevents and treats the application in the influenza medicine in preparation.To achieve these goals, the present invention adopts following technical scheme:
1, with dihydromyricetin 300g and starch 175g uniform mixing, add concentration and be 14% starch slurry 13g and stir the system soft material, to granulate, dry back adds micropowder silica gel, granulate, tabletting is processed 1000 altogether, and every heavily is about 0.5g.
2, confirm that through in vitro tests dihydromyricetin has the obvious suppression effect to influenza virus.
3, the antivirus test result shows in the animal body: dihydromyricetin has good inhibitory effect to influenza virus in the mice body.
4, adopt the single oral administration, the toxic reaction that the maximum dosage that allows on the observational technique is produced mice by the reagent thing.
The result shows: the maximal dose single oral administration of dihydromyricetin to allow, mice does not see toxic reaction.
Beneficial effect of the present invention:
Dihydromyricetin, its main active are flavone compound, and this type of material has multiple peculiar effects such as the free radical of removing, antioxidation, antithrombotic, antitumor, antiinflammatory; And dihydromyricetin is comparatively special a kind of flavone compound, except that the general characteristic with flavone compound, also has the effects such as sickness rate of removing alcoholism, prevention alcoholic liver, fatty liver, the deterioration of inhibition hepatocyte, reducing hepatocarcinoma.Dihydromyricetin preparation of the present invention prevents and treats the application in the influenza medicine, has the effect of good resisiting influenza virus, and is evident in efficacy, and has no side effect, and solved the technical problem that prior art exists.
The specific embodiment
With dihydromyricetin 300g and starch 175g uniform mixing, add concentration and be 14% starch slurry 13g and stir the system soft material, to granulate, dry back adds micropowder silica gel, granulate, tabletting is processed 1000 altogether, and every heavily is about 0.5g.
Embodiment 1. dihydromyricetin are to the cytopathogenic inhibitory action of influenza virus
In the MDCK culture bottle, inoculate 100TCID
508 concentration behind (median tissue culture infective dose) viral liquid doubling dilution were hatched 2 hours for 37 ℃, added 2 times of 7 variable concentrations releasing dilution of maximal non-toxic concentration liquid after HankShi liquid washes 2 times, saw table 1.Continue to cultivate 3 days for 37 ℃, every day, the observation of cell pathological changes and was done the hemagglutinative titer test.Establish virazole positive controls, virus control and cell blank contrast simultaneously, 4 bottles every kind, experimental result is seen table 1.Each medication group is to A
3With the Type B influenza virus certain inhibitory action is arranged all, dihydromyricetin group (1: 4) can suppress Type B virus institute cytopathogenic effect fully.Can produce partial inhibition to first 3 influenza virus cytopathogenic effects, dihydromyricetin (1: 4) is to producing the obvious suppression effect greater than 1: 8 dilution virogenetic cytopathy.
Table 1 dihydromyricetin is to A
3Type and the cytopathogenic inhibitory action of Type B influenza virus
* be " viral dilution degree "; Dihydromyricetin is made into the stock solution of 6.50mg/ml; Virazole 0.25mg/ml
Embodiment 2. dihydromyricetin interior resisting virus are tested
Adopt A
3It is model that type influenza virus liquid inductance dyes mice, observes low dosage and receives reagent thing, middle dosage to receive reagent thing, high dose to receive the influence to Lung Index of mice infected by Influenza virus, pneumonopathy range degree of reagent thing, positive control medicine (virazole).The result sees table 2, and the result shows: receive basic, normal, high three dose groups of reagent thing all can significantly suppress pneumonopathy range degree, lung index and model control group relatively have significant difference on statistics, and prompting receives the reagent thing to have preferably anti-A in the body
3The effect of type influenza virus.
Table 2 dihydromyricetin is to the inhibitory action of influenza virus
Embodiment 3. acute toxicity test in mice
Adopt the single oral administration, the toxic reaction that the maximum dosage that allows on the observational technique is produced mice by the reagent thing.The result shows: after receiving the administration of reagent thing 13.33g/kgbw single oral, mice is movable normal, and no abnormality seens such as outward appearance, behavior, secretions, Excreta change.Observed 14 days continuously, all no abnormality seen reactions, duration of test, the weight of animals normal growth cuts open inspection after the observation period finishes and does not find the unusual pathological change of histoorgan.Prompting: receive the maximal dose 13.33g/kgbw single oral administration of reagent thing to allow, mice does not see toxic reaction.
In sum, the result shows: dihydromyricetin has the effect of two good resisiting influenza virus, and it is evident in efficacy, and has no side effect.
According to the announcement and the instruction of above-mentioned description, those skilled in the art in the invention can also change and revise above-mentioned embodiment.Therefore, the specific embodiment that discloses and describe above the present invention is not limited to also should fall in the protection domain of claim of the present invention modifications more of the present invention and change.In addition, although used some specific terms in this description, these terms are explanation for ease just, the present invention is not constituted any restriction.
Claims (2)
1. dihydromyricetin is prevented and treated the application in the influenza medicine in preparation, it is characterized in that: this prevents and treats the method for preparing of influenza medicine: with dihydromyricetin and starch uniform mixing, add starch slurry and stir the system soft material; Granulate; Dry back adds micropowder silica gel, granulate, tabletting; Process 1000 altogether, every heavily is about 0.5g.
2. dihydromyricetin according to claim 1 is prevented and treated the application in the influenza medicine in preparation, it is characterized in that: dihydromyricetin ingredient in tablets proportioning is: dihydromyricetin 300g, starch 175g, 14% starch slurry 13g, process 1000 altogether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101234718A CN102772398A (en) | 2011-05-13 | 2011-05-13 | Application of dihydromyricetin in preparation of drug preventing and treating influenza |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101234718A CN102772398A (en) | 2011-05-13 | 2011-05-13 | Application of dihydromyricetin in preparation of drug preventing and treating influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102772398A true CN102772398A (en) | 2012-11-14 |
Family
ID=47117662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101234718A Pending CN102772398A (en) | 2011-05-13 | 2011-05-13 | Application of dihydromyricetin in preparation of drug preventing and treating influenza |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102772398A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107898778A (en) * | 2017-11-16 | 2018-04-13 | 南方医科大学 | Application of the myricetin in anti-influenza virus medicament is prepared |
| CN108354923A (en) * | 2017-11-16 | 2018-08-03 | 南方医科大学 | Application of the dihydromyricetin in preparing anti-influenza virus medicament |
| CN114948936A (en) * | 2022-05-05 | 2022-08-30 | 中国科学院华南植物园 | Natural antiviral atomized liquid and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1605335A (en) * | 2003-05-30 | 2005-04-13 | 任启生 | Antivirus dihydromyricetin and myricetin containing pharmaceutical composition |
| CN1644199A (en) * | 2003-05-30 | 2005-07-27 | 任启生 | Use of ampeloptin in preparation of antivirus medicines |
| CN102038190A (en) * | 2009-10-23 | 2011-05-04 | 任启生 | Application of ampelopsin to preparation of anti-mutagenic health-care foods and medicaments |
-
2011
- 2011-05-13 CN CN2011101234718A patent/CN102772398A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1605335A (en) * | 2003-05-30 | 2005-04-13 | 任启生 | Antivirus dihydromyricetin and myricetin containing pharmaceutical composition |
| CN1644199A (en) * | 2003-05-30 | 2005-07-27 | 任启生 | Use of ampeloptin in preparation of antivirus medicines |
| CN102038190A (en) * | 2009-10-23 | 2011-05-04 | 任启生 | Application of ampelopsin to preparation of anti-mutagenic health-care foods and medicaments |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107898778A (en) * | 2017-11-16 | 2018-04-13 | 南方医科大学 | Application of the myricetin in anti-influenza virus medicament is prepared |
| CN108354923A (en) * | 2017-11-16 | 2018-08-03 | 南方医科大学 | Application of the dihydromyricetin in preparing anti-influenza virus medicament |
| CN114948936A (en) * | 2022-05-05 | 2022-08-30 | 中国科学院华南植物园 | Natural antiviral atomized liquid and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1316968C (en) | Application of indole-2,3-diketone in preparing medication for antivirus or immunopotenfiator | |
| CN111773228A (en) | Application of carbenoxolone in preparation of anti-Zika virus drugs | |
| CN111135184A (en) | Application of GS-441524 in preparation of novel coronavirus SARS-CoV-2 inhibitor | |
| CN106668002A (en) | Applications of Gramine and derivatives thereof to preparation of medicaments for resisting adenovirus Type 7 | |
| CN113082049A (en) | New application of potassium iodide or composition containing potassium iodide in preventing or treating African swine fever | |
| CN102772398A (en) | Application of dihydromyricetin in preparation of drug preventing and treating influenza | |
| CN104490909A (en) | Application of derivative of caffeic acid in preparation of medicine for resisting RSV (respiratory syncytial virus) | |
| CN101317904B (en) | Uses of smoked plum extract in resisting virus, bacteria, mycoplasma or chlamydia of livestock and poultry | |
| RU2738719C1 (en) | Agent for treating coronavirus, retrovirus infections and hepatitis c | |
| CN107648297A (en) | A kind of fulvoushair honeysuckle flower extract, the preparation containing the extract and the application in field of medicaments | |
| CA2465062C (en) | Preventive and/or therapeutic agent for viral infection | |
| Stefanou et al. | Pomegranate as an anti-viral agent and immune system stimulant | |
| CN101695511A (en) | Pomegranate rind extract and production method and application thereof | |
| CN111265538B (en) | Application of periplocin in preparing medicine for killing fish ectoparasite | |
| CN1813779A (en) | Use of naringin for preparing medicine for preventing cold | |
| CN115040497A (en) | Application of paeonol derivative in preventing and treating leukoplakia syndrome | |
| CN107320481A (en) | Application of the tannic acid in killing and preventing aquatic livestock vermin | |
| CN108014129A (en) | Application of the iron ion in RNA virus is suppressed | |
| CN101946784B (en) | Application of ginkgolides B to preparation of tobacco mosaic virus resistant medicament | |
| CN101946771A (en) | Application of Saikosaponin A to preparing pesticide for resisting tobacco mosaic virus (TMV) | |
| CN105381024A (en) | Pharmaceutical composition for treating chicken coccidiosis and preparation method thereof | |
| CN108261417B (en) | Compound florfenicol preparation for aquatic animals and preparation method thereof | |
| WO2006053487A1 (en) | The use of vegetable anthraquinone derivatives and vegetable polysaccharides for treating human immunodeficiency virus (hiv) | |
| CN103070876B (en) | The compositions that the anti-encephalitis b virus of one class infects and application thereof | |
| CN107648249B (en) | Application of the desgalactotigonin in the drug for preparing prevention influenza infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121114 |